FDA approves Geron’s RYTELO for MDS associated anaemia
2024-06-07
上市批准临床3期临床结果疫苗
Preview
来源: Pharmaceutical Technology
The treatment is indicated for use in adults with low to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anaemia. Credit: LindseyRN / Shutterstock.
The US Food and Drug Administration (FDA) has granted approval for Geron’s RYTELO (imetelstat) for adults with low to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anaemia.
Recommended Buyer's Guides
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
The approval marks a significant milestone for patients requiring red blood cell transfusions four or more times over eight weeks and who are unresponsive to, have lost response to, or are not eligible for erythropoiesis-stimulating agents.
The FDA’s decision is grounded in the positive results from the IMerge Phase III clinical trial.
RYTELO demonstrated a significant increase in red blood cell transfusion independence compared to placebo.
The trial’s primary and key secondary endpoints were met, showcasing RYTELO’s ability to provide durable and sustained responses for patients with MDS.
See Also:FDA recommends updated Covid-19 vaccinesCovid-19 vaccines targeting JN.1
Preview
来源: Pharmaceutical Technology
India’s DCGI approves Orchid Pharma’s API Enmetazobactam
Preview
来源: Pharmaceutical Technology
In the trial, the safety profile of RYTELO was well-characterised with the most common adverse reactions being manageable cytopenias.
Neutropenia and thrombocytopenia were the most frequent Grade 3/4 side effects, typically resolving within a short timeframe
Geron chairman and CEO John Scarlett stated: “With the approval and availability of RYTELO, we believe eligible patients with lower-risk MDS can potentially experience meaningful clinical benefit, particularly the potential for greater than 24 weeks of freedom from the burden of red blood cell transfusions and symptomatic anaemia.
“The approval of RYTELO as the first telomerase inhibitor is a testament to the power of our science and the passion of our people to innovate in the field of blood cancer. As we celebrate the momentous milestone, I would like to thank the patients and families, advocates, clinicians, study coordinators, site personnel, scientists and Geron employees and collaborators past and present whose participation was integral to this achievement and to supporting our transformation into a commercial company.”
In March 2024, advisers to the US Food and Drug Administration (FDA) defended Geron‘s imetelstat, saying that the benefits outweighed the risks associated with the treatment, based on data from Phase III IMerge trial in MDS patients.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。